Summary
2.00 -0.06(-2.68%)09/27/2024
Heron Therapeutics Inc (HRTX)
Heron Therapeutics Inc (HRTX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.21 | -2.68 | 3.64 | -41.41 | -27.06 | 101.52 | -89.82 | -99.66 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.00 | |
| Open | 2.07 | |
| High | 2.14 | |
| Low | 1.99 | |
| Volume | 1,582,728 | |
| Change | -0.05 | |
| Change % | -2.21 | |
| Avg Volume (20 Days) | 1,780,113 | |
| Volume/Avg Volume (20 Days) Ratio | 0.89 | |
| 52 Week Range | 0.50 - 3.93 | |
| Price vs 52 Week High | -49.24% | |
| Price vs 52 Week Low | 299.00% | |
| Range | -3.62 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 311 | |
| EBIDTA | -61,880,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.1800 | |
| WallStreet Target Price | 6.75 | |
| Book Value | -0.2250 | |
| Earnings Per Share | -0.5500 | |
| EPS Estimate Current Quarter | -0.0900 | |
| EPS Estimate Next Quarter | -0.0700 | |
| EPS Estimate Current Year | -0.1700 | |
| EPS Estimate Next Year | 0.0100 | |
| Diluted EPS (TTM) | -0.5500 | |
| Revenues | ||
| Profit Marging | -0.6128 | |
| Operating Marging (TTM) | -0.1384 | |
| Return on asset (TTM) | -0.1845 | |
| Return on equity (TTM) | -24.0888 | |
| Revenue TTM | 132,099,000 | |
| Revenue per share TTM | 0.9040 | |
| Quarterly Revenue Growth (YOY) | 0.1710 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -50,508,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 12.6037 | |
| Revenue Enterprise Value | 4.2243 | |
| EBITDA Enterprise Value | -5.1707 | |
| Shares | ||
| Shares Outstanding | 150,652,992 | |
| Shares Float | 122,351,456 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.23 | |
| Insider (%) | 0.69 | |
| Institutions (%) | 75.58 | |
09/25 08:00 EST - prnewswire.com
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- The VAN has the potential to simplify aseptic preparation, while also significantly reducing ZYNRELEF's withdrawal time - The VAN is expected to launch in Q4 2024 SAN DIEGO , Sept. 25, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Prior Approval Supplement Application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN.
09/03 08:00 EST - prnewswire.com
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer.
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
SAN DIEGO , Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer.
08/06 20:31 EST - zacks.com
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
08/06 19:46 EST - zacks.com
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.35 per share a year ago.
08/06 16:05 EST - prnewswire.com
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success.
Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023 ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success.
07/30 16:05 EST - prnewswire.com
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights.
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights.
07/15 08:00 EST - prnewswire.com
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outpatient departments ("HOPDs") and ASCs was issued by the Centers for Medicare & Medicaid Services ("CMS").
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that ZYNRELEF® (bupivacaine and meloxicam) is included in the proposed 2025 Non-Opioid Policy for Pain Relief under the Medicare hospital Outpatient Prospective Payment System ("OPPS") and the Medicare Ambulatory Surgical Center ("ASC") payment system (the "Proposed Rule") as a qualifying product effective April 1, 2025. This Proposed Rule for payment within hospital outpatient departments ("HOPDs") and ASCs was issued by the Centers for Medicare & Medicaid Services ("CMS").
07/11 13:02 EST - zacks.com
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
07/11 08:11 EST - zacks.com
New Strong Buy Stocks for July 11th
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024.
New Strong Buy Stocks for July 11th
SKIL, INKT, MLCO, GTLB, and HRTX have been added to the Zacks Rank #1 (Strong Buy) List on July 11, 2024.
07/02 08:00 EST - prnewswire.com
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 SAN DIEGO , July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.
05/29 08:05 EST - prnewswire.com
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion of the FDA's review of this PAS within the next several weeks and anticipates an action date on this PAS to be between four (4) and six (6) months.
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
SAN DIEGO, May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the Prior Approval Supplement ("PAS") submission to the U.S. Food and Drug Administration ("FDA") for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN"). Heron expects to receive the assigned action date for completion of the FDA's review of this PAS within the next several weeks and anticipates an action date on this PAS to be between four (4) and six (6) months.
05/24 10:02 EST - zacks.com
5 Small Drug Stocks to Buy From a Recovering Industry
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
5 Small Drug Stocks to Buy From a Recovering Industry
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
05/21 13:01 EST - zacks.com
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
Does Heron Therapeutics (HRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
05/20 01:38 EST - https://www.defenseworld.net
Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post Q2 2024 Earnings of ($0.05) Per Share
Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Analysts at Capital One Financial increased their Q2 2024 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Wednesday, May 15th. Capital One Financial analyst T. Chiang now forecasts that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.07). Capital One Financial has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.10) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.03) EPS, FY2024 earnings at ($0.17) EPS and FY2025 earnings at $0.02 EPS. Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a report on Thursday. Read Our Latest Stock Analysis on HRTX Heron Therapeutics Price Performance Shares of NASDAQ:HRTX opened at $3.20 on Monday. The stock has a market cap of $482.08 million, a price-to-earnings ratio of -5.25 and a beta of 1.73. The company has a 50 day moving average of $2.78 and a 200-day moving average of $2.21. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.29. Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.08. The firm had revenue of $34.23 million for the quarter, compared to analyst estimates of $30.98 million. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. SG Americas Securities LLC acquired a new position in shares of Heron Therapeutics in the 3rd quarter valued at $31,000. Commonwealth Equity Services LLC increased its holdings in shares of Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Heron Therapeutics by 5.8% during the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 19,345 shares during the period. Richmond Brothers Inc. lifted its holdings in shares of Heron Therapeutics by 142.9% during the 3rd quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 60,604 shares in the last quarter. Finally, Monaco Asset Management SAM grew its position in shares of Heron Therapeutics by 72.1% in the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 291,908 shares during the period. Institutional investors own 80.01% of the company’s stock. About Heron Therapeutics (Get Free Report) Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. See Also Five stocks we like better than Heron Therapeutics Stock Dividend Cuts Happen Are You Ready? MarketBeat Week in Review – 5/13 – 5/17 What is the Dow Jones Industrial Average (DJIA)? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Warren Buffett Stocks to Buy Now Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Heron Therapeutics, Inc. (NASDAQ:HRTX) Expected to Post Q2 2024 Earnings of ($0.05) Per Share
Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Analysts at Capital One Financial increased their Q2 2024 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Wednesday, May 15th. Capital One Financial analyst T. Chiang now forecasts that the biotechnology company will post earnings of ($0.05) per share for the quarter, up from their previous forecast of ($0.07). Capital One Financial has a “Overweight” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.10) per share. Capital One Financial also issued estimates for Heron Therapeutics’ Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.03) EPS, FY2024 earnings at ($0.17) EPS and FY2025 earnings at $0.02 EPS. Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Heron Therapeutics in a report on Thursday. Read Our Latest Stock Analysis on HRTX Heron Therapeutics Price Performance Shares of NASDAQ:HRTX opened at $3.20 on Monday. The stock has a market cap of $482.08 million, a price-to-earnings ratio of -5.25 and a beta of 1.73. The company has a 50 day moving average of $2.78 and a 200-day moving average of $2.21. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.29. Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.08. The firm had revenue of $34.23 million for the quarter, compared to analyst estimates of $30.98 million. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently bought and sold shares of HRTX. SG Americas Securities LLC acquired a new position in shares of Heron Therapeutics in the 3rd quarter valued at $31,000. Commonwealth Equity Services LLC increased its holdings in shares of Heron Therapeutics by 5.5% in the third quarter. Commonwealth Equity Services LLC now owns 314,826 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 16,467 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Heron Therapeutics by 5.8% during the third quarter. Bank of New York Mellon Corp now owns 353,395 shares of the biotechnology company’s stock worth $364,000 after purchasing an additional 19,345 shares during the period. Richmond Brothers Inc. lifted its holdings in shares of Heron Therapeutics by 142.9% during the 3rd quarter. Richmond Brothers Inc. now owns 103,009 shares of the biotechnology company’s stock valued at $106,000 after purchasing an additional 60,604 shares in the last quarter. Finally, Monaco Asset Management SAM grew its position in shares of Heron Therapeutics by 72.1% in the 3rd quarter. Monaco Asset Management SAM now owns 696,908 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 291,908 shares during the period. Institutional investors own 80.01% of the company’s stock. About Heron Therapeutics (Get Free Report) Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. See Also Five stocks we like better than Heron Therapeutics Stock Dividend Cuts Happen Are You Ready? MarketBeat Week in Review – 5/13 – 5/17 What is the Dow Jones Industrial Average (DJIA)? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Warren Buffett Stocks to Buy Now Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/07 14:38 EST - seekingalpha.com
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer William Forbes - Executive Vice President, Chief Development Officer Kevin Warner - SVP of Medical Affairs strategy engagements David Barozzino - Vice President of Sales, Acute Care Conference Call Participants Serge Berlanger - Needham Carl Byrnes - Northland Capital Markets Tim Chiang - Capital One Operator Thank you for standing by. My name is Alex and I will be your conference operator today.
Heron Therapeutics, Inc. (HRTX) Q1 2024 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2024 Earnings Conference Call May 7, 2024 8:30 AM ET Company Participants Craig Collard - Chief Executive Officer Ira Duarte - Executive Vice President and Chief Financial Officer William Forbes - Executive Vice President, Chief Development Officer Kevin Warner - SVP of Medical Affairs strategy engagements David Barozzino - Vice President of Sales, Acute Care Conference Call Participants Serge Berlanger - Needham Carl Byrnes - Northland Capital Markets Tim Chiang - Capital One Operator Thank you for standing by. My name is Alex and I will be your conference operator today.
05/07 10:36 EST - zacks.com
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/07 10:05 EST - zacks.com
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.27 per share a year ago.
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.27 per share a year ago.
05/07 08:00 EST - prnewswire.com
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.
Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.
04/30 11:05 EST - zacks.com
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/24 08:00 EST - prnewswire.com
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
SAN DIEGO , April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.